RecruitingNCT04410302

Patient-Derived Xenografts to Reduce Cancer Health Disparities

University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities

Sponsor

University of California, Davis

Enrollment

500 participants

Start Date

Nov 12, 2019

Study Type

OBSERVATIONAL

Conditions

Bladder Carcinoma Gastric Carcinoma Lung Carcinoma Malignant Neoplasm Liver and Intrahepatic Bile Duct Carcinoma

Summary

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.

Eligibility

Min Age: 21 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Biospecimen Collection for people with bladder carcinoma, gastric carcinoma, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 21 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.